Literature DB >> 26021803

Evidence for TLR4 and FcRγ-CARD9 activation by cholera toxin B subunit and its direct bindings to TREM2 and LMIR5 receptors.

Vongsavanh Phongsisay1, Ei'ichi Iizasa2, Hiromitsu Hara2, Hiroki Yoshida3.   

Abstract

Cholera toxin (CTX) is a virulent factor of Vibrio cholerae that causes life-threatening diarrheal disease. Its non-toxic subunit CTB has been extensively studied for vaccine delivery. In immune cells, CTB induces a number of signaling molecules related to cellular activation and cytokine production. The mechanisms by which CTB exerts its immunological effects are not understood. We report here the immunological targets of CTB. The unexpected finding that GM1 ganglioside inhibited NF-κB activation in human monocytes stimulated with CTX and agonists of Toll-like receptors (TLR) suggests the possibility of CTX-TLR interaction. Indeed, CTX-induced IL-6 production was substantially reduced in MyD88(-/-) or TLR4(-/-) macrophages. Ectopic expression of TLR4 was required for CTX-induced NF-κB activation in HEK 293 cells. Furthermore, the inflammatory capacity of CTB was lost in the absence of TLR4, adaptor protein FcRγ, or its downstream signaling molecule CARD9. Attempts have been made to identify CTB-binding targets from various C-type lectin and immunoglobulin-like receptors. CTB targeted not only GM1 and TLR4 but also TREM2 and LMIR5/CD300b. CTB-TREM2 interaction initiated signal transduction through adaptor protein DAP12. The binding of CTB inhibited LMIR5 activation induced by its endogenous ligand 3-O-sulfo-β-d-galactosylceramide C24:1. In summary, CTB targets TLR4, FcRγ-CARD9, TREM2, and LMIR5. These findings provide new insights into the immunobiology of cholera toxin.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Cholera toxin; GM1; Receptor

Mesh:

Substances:

Year:  2015        PMID: 26021803     DOI: 10.1016/j.molimm.2015.05.008

Source DB:  PubMed          Journal:  Mol Immunol        ISSN: 0161-5890            Impact factor:   4.407


  17 in total

1.  On the use of cholera toxin.

Authors:  Elena Chiricozzi; Laura Mauri; Maria Grazia Ciampa; Alessandro Prinetti; Sandro Sonnino
Journal:  Glycoconj J       Date:  2018-04-07       Impact factor: 2.916

2.  A candidate multi-epitope vaccine against SARS-CoV-2.

Authors:  Tamalika Kar; Utkarsh Narsaria; Srijita Basak; Debashrito Deb; Filippo Castiglione; David M Mueller; Anurag P Srivastava
Journal:  Sci Rep       Date:  2020-07-02       Impact factor: 4.379

Review 3.  TREM2-Ligand Interactions in Health and Disease.

Authors:  Daniel L Kober; Tom J Brett
Journal:  J Mol Biol       Date:  2017-04-19       Impact factor: 5.469

4.  CARD9 mediates necrotic smooth muscle cell-induced inflammation in macrophages contributing to neointima formation of vein grafts.

Authors:  Yan Liu; Ying Wang; Hongtao Shi; Lixin Jia; Jizhong Cheng; Wei Cui; Huihua Li; Ping Li; Jie Du
Journal:  Cardiovasc Res       Date:  2015-08-04       Impact factor: 10.787

5.  Pathophysiological mechanisms of diarrhea caused by the Vibrio cholerae O1 El Tor variant: an in vivo study in mice.

Authors:  Saravut Satitsri; Pawin Pongkorpsakol; Potjanee Srimanote; Varanuj Chatsudthipong; Chatchai Muanprasat
Journal:  Virulence       Date:  2016-05-24       Impact factor: 5.882

Review 6.  Cholera: an overview with reference to the Yemen epidemic.

Authors:  Ali A Rabaan
Journal:  Front Med       Date:  2018-06-22       Impact factor: 4.592

Review 7.  Cholera Toxin Subunit B as Adjuvant--An Accelerator in Protective Immunity and a Break in Autoimmunity.

Authors:  Thomas Stratmann
Journal:  Vaccines (Basel)       Date:  2015-07-24

Review 8.  CARD9 as a potential target in cardiovascular disease.

Authors:  Matthew R Peterson; Samantha E Haller; Jun Ren; Sreejayan Nair; Guanglong He
Journal:  Drug Des Devel Ther       Date:  2016-11-22       Impact factor: 4.162

9.  The Nontoxic Cholera B Subunit Is a Potent Adjuvant for Intradermal DC-Targeted Vaccination.

Authors:  Laura Antonio-Herrera; Oscar Badillo-Godinez; Oscar Medina-Contreras; Araceli Tepale-Segura; Alberto García-Lozano; Lourdes Gutierrez-Xicotencatl; Gloria Soldevila; Fernando R Esquivel-Guadarrama; Juliana Idoyaga; Laura C Bonifaz
Journal:  Front Immunol       Date:  2018-09-27       Impact factor: 7.561

Review 10.  TREM2 in Neurodegenerative Diseases.

Authors:  Taylor R Jay; Victoria E von Saucken; Gary E Landreth
Journal:  Mol Neurodegener       Date:  2017-08-02       Impact factor: 14.195

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.